This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Behind Race Oncology’s quest to prevent chemo from being worse than the disease
Race Oncology is reformulating bisantrene (RAC-220) to prevent chemotherapy-induced heart damage, with a phase 1 cardioprotection trial planned for early 2025. The trial will enroll 25-40 patients across multiple sites. The company has also reported promising results from a phase 1b/2 trial using the original bisantrene formulation (RC-110) in treating acute myeloid leukemia.
Read the full article via this link